Medical research stocks took a bath Thursday, helped by BillionToOne's report, featuring a beat but no guidance hike.
Why BillionToOne Plummeted 36%, Leading A Medtech Sell-Off
Licensing
10:52 AM ET 08/06/2026
Medical research stocks took a bath Thursday, led by BillionToOne's (BLLN) second-quarter report, featuring a widespread beat but no guidance raise. The company is a victim of its own success, said William Blair analyst Matt Larew. Up until the close on Wednesday, BillionToOne stock had climbed more than 84% since putting out its first-quarter report on May 6. "Both the…
BillionToOne stock fell after hours after reporting second-quarter financial results.
Thermo Fisher stock led a medtech rebound Thursday, easing investors' fears of continued malaise for medical research.
RBC's $22 price target implies an upside of 74% for shares of Biohaven.
Insulet stock crashed Wednesday after lowering sales guidance for its body-worn insulin pump in the back half of the year.
Celcuity stock crashed Tuesday on disappointing results for its three-drug approach to advanced breast cancer.
Israeli digital X-ray developer Nanox was once seen as medical imaging’s next big thing; its latest reports, with a going concern…
